Malignant pleural mesothelioma: The standard of care and challenges for future management

Critical Reviews in Oncology/Hematology

Volumn 78, Issue 2, 2011, Pages 92-111

  Van Meerbeeck, Jan P ^a   Scherpereel, Arnaud ^b   Surmont, Veerle F ^a   Baas, Paul ^c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cancer; Chemotherapy; Guidelines; Mesothelioma; Palliation; Pleura; Pleurodesis; Radiotherapy; Supportive care; Surgery; Treatment

Indexed keywords

ASBESTOS; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DOXYCYCLINE; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; INTERFERON; INTERLEUKIN 2 DERIVATIVE; INTERLEUKIN DERIVATIVE; IRINOTECAN; METHOTREXATE; MITOMYCIN; NAVELBINE; OPIATE; OXALIPLATIN; PEMETREXED; PLATINUM; RALTITREXED; RANPIRNASE; THALIDOMIDE; UNINDEXED DRUG;

ANXIETY DISORDER; ASBESTOSIS; ASCITES; BRONCHOPLEURAL FISTULA; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER PAIN; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; DRUG EFFICACY; DYSPNEA; HUMAN; LENGTH OF STAY; LOW DRUG DOSE; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PAIN ASSESSMENT; PALLIATIVE THERAPY; PLEURA; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURECTOMY; PLEURODESIS; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; STENT; THORACOSCOPY; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; VIDEO ASSISTED THORACOSCOPIC SURGERY;

HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; STANDARD OF CARE;

EID: 79953326383     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.04.004     Document Type: Review

References (144)

1. Scherpereel A., Astoul P., Baas P., et al. Guidelines of the ERS/ESTS for management of malignant pleural mesothelioma. Eur Resp J 2010, 35:479-495.
2. Pass H.I., Carbone M. Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 2009, 21:97-104.
3. Robinson B.W., Musk A.W., Lake R.A. Malignant mesothelioma. Lancet 2005, 366(9483):397-408.
4. UICC Prognostic factors in cancer 2006, 165-168. Wiley-Liss, ISBN-13978-0-470-03801-7. 3rd ed. M.K. Gospodarowicz, B. O'Sullivan, L.H. Sobin (Eds.).
5. Eibel R., Tuengerthal S., Schoenberg S.O. The role of new imaging techniques in diagnosis and staging of malignant pleural mesothelioma. Curr Opin Oncol 2003, 15(2):131-138.
6. Wang Z.J., Reddy G.P., Gotway M.B., et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics 2004, 24(1):105-119.
7. Travis W.D.B.E., Müller-Hermelink H.K., Harris C.C. World Health Organization classification of tumours. Tumours of the lung, pleura, thymus and heart 2004, IARC, Lyon, France.
8. Rusch V.W. A Proposed New international TNM staging system for malignant pleural mesothelioma. Chest 1995, 108:1122-1128. The International Mesothelioma Interest Group.
9. Wittekind C., Hutter G.F., Klimpfinger R.V.P., Sobin M.L.H. TNM atlas 2004, UICC, Springer, Berlin, pp. 169-176. 5th ed.
10. Heelan R.T., Rusch V.W., Begg C.B., Panicek D.M., Caravelli J.F., Eisen C. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. Am J Roentgenol 1999, 172:1039-1047.
11. Francart J., Vaes E., Henrard S., et al. A Prognostic index for progression free survival in malignant mesothelioma with application to the design of phase II trial: an analysis of 10 combined EORTC trials. Eur J Cancer 2009, 45(13):2304-2311. [IF: 4.475].
12. Van Meerbeeck J.P., Boyer M. Consensus report: pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma. Lung Cancer 2005, 49(Suppl. 1):S123-S127.
13. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(14):2636-2644.
14. Curran D., Sahmoud T., Therasse P., van Meerbeeck J.P., Postmus P.E., Giaccone G. Prognostic factors in patients with pleural mesothelioma: the EORTC experience. J. Clin Oncol 1998, 16:145-152.
15. Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15(2):257.
16. Treasure T., Utley M. Ten traps for the unwary in surgical series: a case study in mesothelioma reports. J Thorac Cardiovasc Surg 2007, 133:1414-1418.
17. Spirtas R., Connelly R.R., Tucker M.A. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 1988, 15, 41(4):525-530.
18. Nowak A.K., Stockler M.R., Byrne M.J. Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. J Clin Oncol 2004, 22(15):3172-3180.
19. Video-assisted surgery or talc pleurodesis in treating patients with malignant mesothelioma 2009, NCT00821860, accessed at: October 26, 2009. http://www.clintrials.gov/.
20. Shaw P., Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004, (1). [Art. No.: CD002916.pub2; CD002916.pub2]. 10.1002/14651858.
21. Dresler C.M., Olak J., Herndon J.E., et al. Phase III intergroup study of talc poudrage vs. talc slurry sclerosis for malignant pleural effusion. Chest 2005, 127(3):909-915.
22. Tremblay A., Michaud G. Single-centre experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 2006, 129(2):362-368.
23. Putnam J.B., Light R.W., Rodriguez R.M., Ponn R., et al. A randomised comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 1999, 86(10):1992-1999.
24. Jennings A.-L., Davies A.N., Higgins J.P.T., et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002, 57:939-944.
25. Ben-Aharon I., Gafter-Gvili A., Paul M., Leibovici L., Stemmer S.M. Interventions for alleviating cancer-related dyspnea: a systematic review. J Clin Oncol 2008, 26(14):2396-2404.
26. Corner J., Plant H., A'Hern R., Bailey C. Non-pharmacological intervention for breathlessness in lung cancer. Palliat Med 1996, 10(4):299-305.
27. World Health, Organization, Cancer pain, relief 1986, WHO, Geneva.
28. Jackson M.B., Pounder D., Price C., Matthews A.W., Neville E. Percutaneous cervical cordotomy for the control of pain in patients with pleural mesothelioma. Thorax 1999, 54(3):238-241.
29. Kanpolat Y., Savas A., Ucar T., Torun F. CT-guided percutaneous selective cordotomy for treatment of intractable pain in patients with malignant pleural mesothelioma. Acta Neurochir (Wien) 2002, 144(6):595-599.
30. Boutin C., Rey F., Viallat J.R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomised trial of local radiotherapy. Chest 1995, 108(3):754-758.
31. Bydder S., Phillips M., Joseph D.J., Cameron F., Spry N.A., DeMelker Y., Musk A.W. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer 2004, 91(1):9-10.
32. O'Rourke N., Garcia J.C., Paul J., et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007, 84(1):18-22.
33. Ung Y.C., Yu E., Falkson C., et al. The role of radiation therapy in malignant pleural mesothelioma: a systematic review. Radiother Oncol 2006, 80:13-18.
34. Muirhead R., O'Rourke N. Drain site radiotherapy in malignant pleural mesothelioma: a wasted resource. Eur Respir J 2007, 30(5):1021.
35. Waller D.A., Morritt G.N., Forty J. Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest 1995, 107(5):1454-1456.
36. Soysal O., Karaoglanoglu N., Demiracan S., et al. Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery. Eur J Cardiothorac Surg 1997, 11(2):210-213.
37. Halstead J.C., Lim E., Venkateswaran R.M., et al. Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma. Eur J Surg Oncol 2005, 31(3):314-320.
38. Nakas A., Martin-Ucar A.E., Edwards J.G., Waller D.A. The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2008, 33(1):83-88.
39. Martin-Ucar A.E., Edwards J.G., Rengajaran A., Muller S., Waller D.A. Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control. Eur J Cardiothorac Surg 2001, 20(6):1117-1121.
40. Ellis P., Davies A., Evans K., et al. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 2006, 1:591-601.
41. Muers M.F., Stephens R.J., Fisher P., et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008, 371(9625):1685-1694.
42. Berghmans T., Mascaux L.J., Meert C., Paesmans A.P., Sculier M.J.P. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2003, 245-256.
43. Sørensen J.B., Frank H., Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 2008, 99(1):44-50.
44. Fennell D., Scullin P., Ceresoli G., et al. Tumour response to chemotherapy predicts longer survival in an individual patient meta-analysis of 1205 patients with mesothelioma. J Thorac Oncol 2009, 4(9):S347.
45. Van Meerbeeck J.P., Gaafar R., Manegold C., et al. Randomised phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005, 23(28):6881-6889.
46. Ceresoli G., Castagneto B., Zucali P.A., et al. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer 2008, 8, 99(1):51-56.
47. Santoro A., O'Brien M.E., Stahel R.A., et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008, 3(7):756-763.
48. O'Brien M.E., Watkins D., Ryan C., et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 2006, 17(2):270-275.
49. Van den Bogaert D.P., Pouw E.M., van Wijhe G., Vernhout R.M., et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol 2006, 1(1):25-30.
50. Giaccone G., O'Brien M.E., Byrne M.J., Bard M., Kaukel E., Smit B. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer 2002, 38(Suppl. 8):S19-S24.
51. Harvey V.J., Slevin M.L., Ponder B.A., Blackshaw A.J., Wrigley P.F. Chemotherapy of diffuse malignant mesothelioma, phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer 1984, 54(6):961-964.
52. Porta C., Zimatore M., Bonomi L., et al. Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 2005, 48(3):429-434.
53. Sorensen P.G., Bach F., Bork E., Hansen H.H. Randomised trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 1985, 69(12):1431-1432.
54. Fennell D.A., Steele J.P., Shamash J., et al. Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer 2007, 109(1):93-99.
55. Sorensen J.B., Sundstrom S., Perell K., Thielsen A.K. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol 2007, 2(2):147-152.
56. Zucali P.A., Ceresoli G.L., Garassino I., De Vincenzo F., Cavina R., Campagnoli E., Cappuzzo F., Salamina S., Soto Parra H.J., Santoro A. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008, 112(7):1555-1561.
57. Jassem J., Ramlau R., Santoro A., et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008, 26(10):1698-1704.
58. Reck M., Krzakowski M., Jacek J., et al. Randomised multicentre phase IIIB study of ranpirnase+doxorubicin (DOX) versus DOX in patints with unresectable maligant lmesothelioma. J Clin Oncol 2009, 27(Suppl.):15s. [abstract no. 7507].
59. Dazzi H., Hasleton P.S., Thatcher N., et al. Malignant pleural mesothelioma and epidermal growth factor receptor, Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990, 61:924-926.
60. Govindan R., Kratzke R.A., Herndon J.E., et al. Gefitinib in patients with malignant mesothelioma: a Phase II Study by the Cancer and Leukemia Group B. Clin Cancer Res 2005, 11:2300-2304.
61. Garland L.L., Rankin C., Gandara D.R., et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007, 25:2406-2413.
62. Cortese J.F., Gowda A.L., Wali A., et al. Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 2006, 118:521-522.
63. Anonymous A study of cetuximab combined with cisplatin or carboplatin/pemetrexed as first line treatment in patients with malignant pleural mesothelioma 2009, MesoMab, NCT00996567, accessed October 25, 2009. http://www.clinicaltrials.gov/.
64. Edwards J.G., Cox G., Andi A., et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 2001, 85:863-868.
65. Strizzi L., Catalano A., Vianale G., et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001, 193:468-475.
66. Ohta Y., Shridhar V., Bright R.K., et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999, 81:54-61.
67. Karrison T., Kindler H., Gandara D., et al. Final analysis of a multi-centre, double-blind, placebo-controlled, randomised phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J Clin Oncol 2007, 25. [abstract no. 7526].
68. Bevacizumab (Avastin) and Erlotinib (Tarceva) in previously treated mesothelioma 2009, NCT00137826, accessed October 25, 2009. http://www.clinicaltrials.gov/.
69. Anonymous Carboplatin, bevacizumab and pemetrexed in the first-line treatment of patients with MPM 2009, NCT00604461, accessed October 25, 2009. http://www.clinicaltrials.gov/.
70. Janne P., Wang X., Krug L., Hodgson L., Vokes E., Kindler H Sorafenib in malignant mesothelioma (MM): a phase II trial of the Cancer and Leukemia Group B (CALGB 30307). J Clin Oncol 2007, 25. [abstract no. 7707].
71. Richly H., Henning B.F., Kupsch P., et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumours. Ann Oncol 2006, 17:866-873.
72. Sorafenib in treating patients with malignant mesothelioma 2009, NCT00107432, accessed October 25, 2009. http://www.clinicaltrials.gov/.
73. Jahan T.M., Gu L., Wang X., et al. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107). J Clin Oncol 2006, (Suppl. 18):24. [abstract no. 7081].
74. Sunitinib in treating patients with advanced malignant pleural mesothelioma 2009, NCT00392444, accessed October 25, 2009. http://www.clinicaltrials.gov/.
75. A study to find the best dose of SU011248 when given with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumours 2009, NCT00528619, accessed October 25, 2009. http://www.clinicaltrials.gov/.
76. Baas P., Boogerd W., Dalesio O., et al. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005, 48:291-296.
77. Pavlakis N., Abraham R., Harvie R., et al. Thalidomide alone or in combination with cisplatin/gemcitabine in malignant pleural mesothelioma: interim results from two parallel non randomised phase II studies. Lung Cancer 2003, 41(Suppl. 2):S11. [abstract].
78. Kumar-Singh S., Weyler J., Martin M.J., Vermeulen P.B., Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 1999, 189:72-78.
79. Klabatsa A., Sheaff M.T., Steele J.P., Evans M.T., Rudd R.M., Fennell D.A. Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM). Lung Cancer 2006, 51:53-59.
80. Millward M., Parnis F., Byrne M., et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma. Proc Am Soc Clin Oncol 2003, 22. [abstract no. 912].
81. Villano J., Husain A.N., Stadler W.M., et al. A Phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM). Proc Am Soc Clin Oncol 2004, 663. [abstract no. 7200].
82. Mathy A., Baas P., Dalesio O., van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005, 50(1):83-86.
83. Porta C., Mutti L., Tassi G. Negative results of an Italian group for mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007, 59:149-150.
84. Bertino P., Porta C., Barbone D., et al. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax 2007, 62:690-695.
85. Cisplatin, pemetrexed and imatinib mesylate in malignant mesothelioma 2009, NCT00402766, accessed October 25, 2009. http://www.clinicaltrials.gov/.
86. ® in patients with unresectable, refractory, malignant mesothelioma 2009, NCT00551252, accessed October 25, 2009. http://www.clinicaltrials.gov/.
87. Raymond E., Alexandre J., Faivre S., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004, 22:2336-2347.
88. Marks P.A., Richon V.M., Breslow R., Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001, 13:477-483.
89. Deroanne C.F., Bonjean K., Servotte S., et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002, 21:427-436.
90. Krug L.M., Curley T., Schwartz L., et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006, 7:257-261.
91. Suberoylanilide hydroxamic acid vorinostat, MK0683 versus placebo in advanced malignant pleural mesothelioma 2009, NCT00128102, accessed October 25, 2009. http://www.clinicaltrials.gov/.
92. Anonymous PXD101 as second-line therapy in treating patients with malignant mesothelioma of the chest that cannot be removed by surgery 2009, NCT00365053, accessed October 25, 2009. http://www.clinicaltrials.gov/.
93. Fennell D.A., Chacko A., Mutti L. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 2008, 27(9):1189-1197.
94. Sartore-Bianchi A., Gasparri F., Galvani A., Nici L., Darnowski J.W., Barbone D., et al. Bortezomib inhibits nuclear factor-kappa B-dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 2007, 13:5942-5951.
95. Gordon G.J., Mani M., Maulik G., et al. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007, 10.1007/s00280-007-0500-1.
96. Anonymous Bortezomib in treating patients with malignant pleural mesothelioma 2009, NCT00325494, accessed November 3, 2009. http://www.clinicaltrials.gov/.
97. Anonymous Bortezomib and cisplatin as first-line therapy in treating patients with malignant mesothelioma 2009, NCT00458913, accessed October 25, 2009. http://www.clinicaltrials.gov/.
98. Senan S. Indications and limitations of radiotherapy in malignant pleural mesothelioma. Curr Opin Oncol 2003, 15(2):144-147.
99. Maasilta P. Deterioration in lung function following hemithorax irradiation for pleural mesothelioma. Int J Radiat Oncol Biol Phys 1991, 20(3):433-438.
100. Chapman E., Berenstein G., García Diéguez M., Ortiz Z. Radiotherapy for malignant pleural mesothelioma. Cochrane Database Syst Rev 2006, (3). Art. No.: CD003880. 10.1002/14651858.CD003880.pub4.
101. Sugarbaker D.J., Jaklitsch M.T., Bueno R., et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004, 128(1):138-146.
102. Opitz I., Kestenholz P., Lardinois D., et al. Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg 2006, 29:579-584.
103. Sugarbaker D.J. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol 2006, 1:175-176.
104. Baldini E.H., Recht A., Strauss G.M., DeCamp M.M., Swanson S.J., Liptay M.J., Mentzer S.J., Sugarbaker D.J. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 1997, 63(2):334-338.
105. Rusch V.W., Rosenzweig K., Venkatraman E., et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001, 122(4):788-795.
106. Ahamed A., Stevens C.W., Smythe W.R., et al. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2003, 55:768-775.
107. Allen A.M., Czerminska M., Janne P.A., et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006, 65(3):640-645.
108. Rice D.C., Stevens C.W., Correa A.M., et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007, 84(5):1685-1692.
109. Sugarbaker D.J., Flores R.M., Jaklitsch M.T., et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy for malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999, 117:54-63.
110. Flores R.M., Krug L.M., Rosenzweig K.E., et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 2006, 1:289-295.
111. Weder W., Kestenholz P., Taverna C., et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004, 22(September (17)):3451-3457.
112. De Perrot M., Feld R., Cho B.C., et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009, 27(March (9)):1413-1418.
113. Weder W., Stahel R.A., Bernhard J., et al. Multicentre trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007, 18(7):1196-1202.
114. Krug L.M., Pass H.I., Rusch V.W., et al. Multicentre phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009, 27(18):3007-3013.
115. Van Schil P., Baas P., Gaafar R., et al. Phase II feasibility trial of induction chemotherapy (ICT) followed by extrapleural pneumonectomy (EPP) and postoperative radiotherapy (PORT) for cT3N1M0 or less malignant pleural mesothelioma (MPM) (EORTC 08031). J Clin Oncol 2009, 27(15s). [abstract no. 7509].
116. Brunelli A., Charloux A., Bolliger C.T., et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 2009, 34:17-41.
117. British Thoracic Society Standards of Care Committee BTS statement on malignant mesothelioma in the UK. Thorax 2007, 62(Suppl. II):ii1-ii19.
118. Scherpereel A. Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma. Respir Med 2007, 101(6):1265-1276. French Speaking Society for Chest Medicine (SPLF) Experts Group.
119. Ellis P., Davies A.M., Evans W.K., et al. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 2006, 1(6):591-601.
120. Stahel R.A., Weder W., Felip E. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008, 19(Suppl. 2):ii43-ii44. ESMO Guidelines Working Group.
121. NCCN Mesothelioma Panel Members. NCCN clinical practice guidelines in oncology. v.I. 2010, accessed at http://www.nccn.org/.
122. Pinto C, Ardizzoni A,Giacomo Betta P, Facciolo F,Tassi G, et al. Expert Opinions of the First Italian Consensus Conference on the Management of Malignant Pleural Mesothelioma. Am J Clin Oncol 2010 Apr 21. [Epub ahead of print].
123. Chemotherapy in non-small cell lung cancer: a meta-analysis using update data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ 1995, 7311(7010):899-909.
124. Krug L.M., Heelan R.T., Kris M.G., Venkatraman E., Sirotnak F.M. Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma. J Thorac Oncol 2007, 2(4):317-320.
125. Kisliuk .R.L. Deaza analogs of folic acid as antitumour agents. Curr Pharm Des 2003, 9(31):2615-2625.
126. Purcell W.T., Ettinger D.S. Novel antifolate drugs. Curr Oncol Rep 2003, 5(2):114-125.
127. Webber S., Bartlett C.A., Boritzki T.J., et al. AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemother Pharmacol 1996, 37(6):509-517.
128. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584.
129. Talbot D.C., Margery J., Dabouis G., et al. Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 2007, 20, 25(30):4751-4756.
130. Greillier L., Baas P., Welch J.J., Hasan B., Passioukov A. Biomarkers for malignant pleural mesothelioma: current status. Mol Diagn Ther 2008, 12(6):375-390.
131. Hassan R., Bullock S., Premkumar A., et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesotheline expressing mesothelioma, ovarian and pancreatic cancers. Clin Cancer Res 2007, 13:5144-5149.
132. Zhang Y., Xiang L., Hassan R., et al. Synergistic antitumour activity of taxol and immunotoxin SS1P in tumour-bearing mice. Clin Cancer Res 2006, 12:4695-4701.
133. Anonymous A study of MORAb-009 in subjects with pancreatic cancer, mesothelioma or certain types of ovarian or lung cancer 2009, NCT00325494, accessed October 25, 2009. http://www.clinicaltrials.gov/.
134. May R.J., Dao T., Pinilla-Ibarz J., et al. Peptide epitopes from the Wilms' tumour 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumour cells. Clin Cancer Res 2007, 13:4547-4555.
135. Hegmans J.P., Hemmes A., Aerts J.G., Hoogsteden H.C., Lambrecht B.N. Immunotherapy of murine malignant mesothelioma using tumour lysate-pulsed dendritic cells. Am J Respir Crit Care Med 2005, 171(May (10)):1168-1177.
136. Hegmans J.P., Hemmes A., Hammad H., et al. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 2006, 27(June (6)):1086-1095.
137. Hillerdal G., Sorensen J.B., Sundström S., et al. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol 2008, 3(11):1325-1331.
138. Treasure T., Waller D., Swift S., Peto J. Radical surgery for mesothelioma, the epidemic is still to peak and we need more research to manage it. BMJ 2004, 328:237-238.
139. Treasure T., Waller D., Tan C., et al. The mesothelioma and radical surgery randomised controlled trial: the MARS feasibility study. J Thorac Oncol 2009, 4:1254-1258.
140. Rusch V. The MARS trial: resolution of the surgical controversies in mesothelioma?. J Thorac Oncol 2009, 4:1189-1191.
141. Swiss Group for Clinical Cancer Research Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy. A randomised multicentre phase II trial (SAKK 1704) 2009, accessed on November 3, 2009. http://sakk.ch/en/download/105.
142. Rosenzweig K., Krug L., Laser B., et al. Feasibility of pleural Intensity-Modulated Radiation Therapy (IMRT) for malignant mesothelioma. J Thorac Oncol 2009, 4(9):S774.
143. Study using chemotherapy followed by intensity modulated radiation therapy to the pleura in patients with locally advanced but unresectable malignant pleural mesothelioma 2009, NCT00715611, accessed on November 3, 2009. http://www.clinicaltrials.gov/ct2/show/.
144. Wang Z.J., Reddy G.P., Gotway M.P., et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. RadioGraphics 2004, 24:105-119.